Merck Freezes Cordaptive ACHIEVE Trial
This article was originally published in The Pink Sheet Daily
Imaging endpoint stalls cholesterol study, per a monitoring panel’s advice.
You may also be interested in...
At first glance, Merck's Cordaptive is yet another combination drug for cholesterol. But by unlocking the significant medical benefits of niacin, the treatment may represent an important advance. Cordaptive contains an anti-flushing agent which reduces the key side-effect preventing wider niacin use.
Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.
The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.